Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac may get Phase III trial results of COVID-19 vaccine by December, executive says

11/20/2020 | 05:58am EST
Media tour at Chinese vaccine maker Sinovac Biotech in Beijing

JAKARTA (Reuters) - Chinese vaccine maker Sinovac Biotech could have the results of its experimental COVID-19 vaccine from late-stage clinical trials as soon as next month, an executive said on Friday.

Sinovac's CoronaVac is in large late-stage trials in Brazil, Indonesia and Turkey. Preliminary results of early to mid-stage trials showed this week that it triggered a quick immune response but lower levels of antibodies than those seen in people who have recovered from COVID-19.

"Phase III is now running quite well," Weining Meng, senior director of Sinovac, told the Global Town Hall 2020 conference held online. "I guess maybe next month we'll have data available."

The results follow news this month from Pfizer Inc and BioNTech and from Moderna, as well as from Russia, of experimental vaccines proving more than 90% effective, based on interim data from large, late-stage trials.

Brazil and Indonesia are considering CoronaVac for inoculations in the coming months.

Meng said the company's manufacturing deals with local partners, including Indonesia's PT Bio Farma, will help it lower production costs and accelerate delivery once its vaccine gets regulatory approval.

(Reporting by Stanley Widianto; Editing by Clarence Fernandez)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 4.79% 109.99 Delayed Quote.224.65%
EURO / BRAZILIAN REAL (EUR/BRL) 0.54% 6.3746 Delayed Quote.40.72%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.16% 75.975 Delayed Quote.22.05%
US DOLLAR / TURKISH LIRA (USD/TRY) 0.00% 7.8332 Delayed Quote.31.76%
All news about SINOVAC BIOTECH LTD.
04:15aPhilippines secures 2.6 mln doses of AstraZeneca's COVID-19 vaccine
RE
11/23Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - offi..
RE
11/23Sao Paulo expects regulator approval for Sinovac vaccine by January
RE
11/23Q&A : Where are we in the COVID-19 vaccine race?
RE
11/20SINOVAC BIOTECH : Pfizer eyes rapid COVID-19 vaccine roll-out in Latam after U.S..
RE
11/20Britain asks regulator to assess Pfizer vaccine for suitability
RE
11/20UK asks regulator to assess Pfizer vaccine for suitability
RE
11/20Sinovac may get Phase III trial results of COVID-19 vaccine by December, exec..
RE
11/17Brazil to receive China's Sinovac COVID-19 vaccine, eyes Pfizer candidate
RE
11/17Sinovac's COVID-19 vaccine induces quick immune response - study
RE
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 50,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.-6.77%640
CSL LIMITED11.34%102 823
SAMSUNG BIOLOGICS CO.,LTD.84.53%47 765
BIOGEN INC.-18.53%37 201
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%28 818
ALEXION PHARMACEUTICALS, INC.13.67%26 903